Form 4: Inozyme Pharma COO Matthew Winton Reports Stock Purchase Under Employee Stock Purchase Plan

Inozyme Pharma's COO, Matthew Winton, reports acquiring 1,710 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) at a price of $4.45 per share.

Summary

• On September 30, 2024, Matthew Winton, the COO of Inozyme Pharma, Inc., acquired 1,710 shares of common stock.
• The purchase was made through the company's 2020 Employee Stock Purchase Plan (ESPP).
• The price per share was $4.45, representing 85% of the closing price on the last trading day of the purchase period (September 30, 2024).
• Following the transaction, Winton directly owns 4,898 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects routine insider activity (ESPP purchase) which signals confidence, but isn't a major event.

Positives

• The COO's participation in the ESPP demonstrates confidence in the company's future.
• The ESPP provides employees with an opportunity to acquire company stock at a discounted price.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders by demonstrating management's confidence in the company.

Key Dates